Vanda Pharmaceuticals
VNDA
198 hedge funds and large institutions have $851M invested in Vanda Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 65 increasing their positions, 67 reducing their positions, and 22 closing their positions.
268% more call options, than puts
Call options by funds: $17.8M | Put options by funds: $4.85M
77% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 22
9% more funds holding
Funds holding: 182 → 198 (+16)
3% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 67
1.88% less ownership
Funds ownership: 99.29% → 97.41% (-1.9%)
10% less capital invested
Capital invested by funds: $947M → $851M (-$95.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$15.4M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.67M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$6.36M |
| 4 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$4.95M |
| 5 |
Two Sigma Investments
New York
|
+$3.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$33.7M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$16.7M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$12.1M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$5.63M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.66M |
VNDA Hedge Fund Activity: Q4 2021 in Review
198 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2021, worth a combined $851M — down 10% from $947M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new VNDA positions and 22 closed out — a net gain of 17 holders — while 65 added to existing stakes and 67 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $15.4M. The largest seller was Armistice Capital, exiting entirely with an estimated $33.7M sold.
- 198 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2021, up from 182 in Q3 2021.
- Funds reported $851M of Vanda Pharmaceuticals stock for Q4 2021, down 10% quarter-over-quarter.
- 39 funds opened new Vanda Pharmaceuticals positions in Q4 2021 and 22 closed out, a net change of +17 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2021 was Goldman Sachs, an estimated $15.4M added.
- The largest Vanda Pharmaceuticals seller in Q4 2021 was Armistice Capital, an estimated $33.7M sold.
Based on aggregated 13F filings for Q4 2021.